CytoDyn Inc. (CYDY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, CytoDyn Inc. (CYDY) es una empresa del sector Healthcare valorada en 0. Calificado con 47/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026CytoDyn Inc. (CYDY) Resumen de Asistencia Médica y Tuberías
CytoDyn Inc. is a clinical-stage biotechnology firm specializing in the development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. Its focus areas include COVID-19, oncology (metastatic triple-negative breast cancer and micro-satellite stable colorectal cancer), and collaborations like the one with Creatv Bio, positioning it within the competitive biotechnology sector.
Tesis de Inversión
CytoDyn Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is largely dependent on the successful clinical development and regulatory approval of leronlimab. Key value drivers include positive Phase 2 trial results for its oncology programs and potential partnerships for commercialization. The company's beta of 1.27 indicates higher volatility compared to the market. A significant risk factor is the company's reliance on a single drug candidate and the inherent uncertainty of clinical trials. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the company's progress. As of 2026-03-16, the company's market capitalization is $0.33 billion, reflecting investor sentiment and expectations regarding future success.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- CytoDyn Inc. is focused on the clinical development of leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor.
- Leronlimab is currently in Phase 2 clinical development for micro-satellite stable colorectal cancer and solid tumors, including metastatic triple-negative breast cancer.
- The company has a collaboration with Creatv Bio to advance its research and development efforts.
- CytoDyn's market capitalization is $0.33 billion as of 2026-03-16, reflecting investor sentiment.
- The company's beta of 1.27 indicates higher volatility compared to the market.
Fortalezas
- Novel therapeutic approach targeting the CCR5 receptor.
- Potential applications in multiple therapeutic areas.
- Collaboration with Creatv Bio.
Debilidades
- Reliance on a single drug candidate.
- Limited financial resources.
- High risk of clinical trial failure.
Catalizadores
- Upcoming: Phase 2 clinical trial results for micro-satellite stable colorectal cancer (timeline unknown).
- Upcoming: Phase 2 clinical trial results for metastatic triple-negative breast cancer (timeline unknown).
- Ongoing: Potential for new partnerships and collaborations.
- Ongoing: Regulatory updates regarding leronlimab's development.
Riesgos
- Potential: Clinical trial failures for leronlimab.
- Potential: Regulatory delays or rejection of leronlimab.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and dependence on external funding.
- Ongoing: Patent expiration and intellectual property challenges.
Oportunidades de crecimiento
- Expansion into New Oncology Indications: CytoDyn has the opportunity to expand the application of leronlimab into additional oncology indications beyond micro-satellite stable colorectal cancer and metastatic triple-negative breast cancer. This could involve targeting other solid tumors or hematological malignancies. The oncology drug market is projected to reach $250 billion by 2030, offering a substantial market opportunity for successful therapies. This expansion would require further clinical trials and regulatory approvals, with a potential timeline of 3-5 years.
- Partnerships and Collaborations: CytoDyn can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of leronlimab. These partnerships could provide access to additional funding, expertise, and distribution channels. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation, with deal values reaching billions of dollars annually. A successful partnership could significantly enhance CytoDyn's market position and financial resources, with potential deals materializing within the next 1-2 years.
- Advancement of COVID-19 Program: Although the COVID-19 pandemic has subsided, CytoDyn could explore potential applications of leronlimab in treating long-term COVID-19 symptoms or other viral infections. The long-COVID market is still emerging, but some analysts estimate it could reach billions of dollars in the coming years. This would require additional clinical trials and regulatory approvals, with a potential timeline of 2-4 years.
- Geographic Expansion: CytoDyn can expand its clinical trials and commercialization efforts into new geographic regions, particularly in Asia and Europe, where there is a growing demand for innovative cancer therapies. The global oncology market is expanding rapidly, with emerging markets offering significant growth opportunities. This expansion would require regulatory approvals and partnerships with local distributors, with a potential timeline of 3-5 years.
- Leveraging Orphan Drug Designation: CytoDyn can seek orphan drug designation for leronlimab in specific rare cancer subtypes. Orphan drug designation provides several benefits, including market exclusivity and tax incentives, which can enhance the commercial viability of the drug. The orphan drug market is growing faster than the overall pharmaceutical market, driven by unmet medical needs and regulatory support. This designation could be pursued within the next 1-2 years, depending on the specific cancer subtype targeted.
Oportunidades
- Expansion into new oncology indications.
- Strategic partnerships with larger pharmaceutical companies.
- Advancement of COVID-19 program.
Amenazas
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Patent expiration.
Ventajas competitivas
- Patent protection for leronlimab (limited information available).
- Clinical data supporting the efficacy of leronlimab (limited information available).
- Strategic collaborations with research institutions and other companies.
Acerca de CYDY
CytoDyn Inc., formerly RexRay Corporation, was founded in 2002 and is headquartered in Vancouver, Washington. It operates as a clinical-stage biotechnology company dedicated to developing innovative treatments for a range of therapeutic indications. The company's primary focus is on the clinical development of leronlimab, a humanized monoclonal antibody that targets the C-C chemokine receptor type 5 (CCR5). Leronlimab is being investigated for its potential in treating COVID-19, micro-satellite stable colorectal cancer, and solid tumors, including metastatic triple-negative breast cancer. CytoDyn's approach involves strategic collaborations, such as its partnership with Creatv Bio, to advance its research and development efforts. The company is currently in Phase 2 clinical development for several of its oncology programs. CytoDyn aims to address unmet medical needs through its targeted therapies, navigating the complex regulatory landscape to bring its products to market.
Qué hacen
- Develops leronlimab, a humanized monoclonal antibody.
- Targets the CCR5 receptor for therapeutic intervention.
- Conducts clinical trials for COVID-19 treatment.
- Investigates leronlimab for micro-satellite stable colorectal cancer.
- Explores leronlimab's potential in treating metastatic triple-negative breast cancer.
- Collaborates with Creatv Bio for research and development.
Modelo de Negocio
- Focuses on developing and commercializing leronlimab.
- Generates revenue through potential future sales of leronlimab.
- Relies on partnerships and collaborations for funding and expertise.
Contexto de la Industria
CytoDyn Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for oncology drugs is substantial and growing, driven by an aging population and increasing cancer incidence rates. Companies like CytoDyn are striving to develop novel therapies that address unmet medical needs. The success of biotechnology companies depends on their ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy. The biotechnology industry is subject to rapid technological advancements and evolving scientific understanding, requiring companies to remain innovative and adaptable.
Clientes Clave
- Patients with COVID-19 (potential future market).
- Patients with micro-satellite stable colorectal cancer (clinical trial participants).
- Patients with metastatic triple-negative breast cancer (clinical trial participants).
Finanzas
Gráfico e información
Precio de la acción de CytoDyn Inc. (CYDY): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· 29 ene 2020
-
Stocks That Hit 52-Week Highs On Friday
· 27 dic 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CYDY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CYDY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CYDY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Información del mercado OTC de CYDY
The OTCQB Venture Market is the middle tier of the over-the-counter (OTC) market, designed for developing companies. Unlike the NYSE or NASDAQ, OTCQB companies have more lenient listing requirements, making it accessible for smaller or early-stage businesses. To qualify for OTCQB, companies must meet minimum financial standards, follow SEC reporting guidelines (or the Pink Basic Disclosure Guidelines if they are not SEC reporting), and undergo an annual verification process. This tier offers more visibility and credibility compared to the lower OTC Pink market but less than the major exchanges.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited regulatory oversight compared to major exchanges.
- Lower liquidity and higher price volatility.
- Potential for less stringent financial reporting requirements.
- Increased risk of fraud or manipulation.
- Dependence on a single drug candidate.
- Verify the company's financial disclosures on the OTC Markets website.
- Review the company's SEC filings (if applicable).
- Assess the company's management team and their track record.
- Evaluate the company's clinical trial data and regulatory prospects.
- Analyze the company's competitive landscape and market potential.
- Monitor the company's news releases and investor relations materials.
- Understand the risks associated with investing in OTCQB-listed companies.
- OTCQB listing indicates a certain level of financial and reporting compliance.
- Collaboration with Creatv Bio suggests external validation of the company's technology.
- Clinical trials underway for leronlimab indicate ongoing research and development efforts.
Acciones de CytoDyn Inc.: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar CYDY?
CytoDyn Inc. (CYDY) actualmente tiene una puntuación IA de 47/100, indicando puntuación baja. Fortaleza clave: Novel therapeutic approach targeting the CCR5 receptor.. Riesgo principal a monitorear: Potential: Clinical trial failures for leronlimab.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CYDY?
CYDY actualmente puntúa 47/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CYDY?
Los precios de CYDY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CYDY?
La cobertura de analistas para CYDY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CYDY?
Las categorías de riesgo para CYDY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures for leronlimab.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CYDY?
La relación P/E para CYDY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CYDY sobrevalorada o infravalorada?
Determinar si CytoDyn Inc. (CYDY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CYDY?
CytoDyn Inc. (CYDY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available on specific financial metrics and analyst coverage.
- OTC listing increases investment risk.